Oncology

Gloucester Pharmaceuticals presents romidepsin data for T cell lymphomas at conference

Published in Blood Weekly, February 1st, 2007

Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced that two abstracts detailing updated results from clinical trials of the company's lead product candidate, romidepsin (formerly known as depsipeptide, FK228), for the treatment of T-cell lymphomas were presented at the 2006 American Society of Hematology's 48th Annual Meeting in Orlando, Florida.

Dr. Adam Lerner of the Boston University School of Medicine presented "Romidepsin (Depsipeptide, FK228) Induces Clinically Significant Responses in Treatment-Refractory CTCL: Interim Report of a Phase II Multicenter Study" in a general poster session. The poster reported on...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2007-02-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry